 altretamin altretamin nation cancer institute-design group antineoplast agent treatment advanc ovarian cancer altretamin lipid-solubl drug avail oral administr capsul drug metabol oxid methylol deriv formaldehyd unclear metabolit major speci respons cytotox primari mechan cytotox singl agent treatment ovarian cancer respons rate similar activ agent diseas percent major util altretamin combin agent cyclophosphamid doxorubicin fluorouracil melphalan cisplatin trial contribut altretamin multiag combin dose-limit toxic gastrointestin nausea anorexia neurotox peripher neurotox therapeut role altretamin limit toxic profil similar cisplatin activ agent ovarian cancer use patient candid standard platinum-bas regimen